Ionis Pharmaceuticals, Inc. Proceeds from Convertible Debt
Ionis Pharmaceuticals, Inc. (IONS) reported Proceeds from Convertible Debt of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2025-02-19
- Ionis Pharmaceuticals, Inc. proceeds from convertible debt for the quarter ending 2024-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from convertible debt for the quarter ending 2024-09-30 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from convertible debt for the quarter ending 2023-12-31 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from convertible debt for the quarter ending 2023-09-30 was $0.00.
- Ionis Pharmaceuticals, Inc. proceeds from convertible debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Ionis Pharmaceuticals, Inc. proceeds from convertible debt for fiscal 2023 was $575.00M.
- Ionis Pharmaceuticals, Inc. proceeds from convertible debt for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Ionis Pharmaceuticals, Inc. proceeds from convertible debt for fiscal 2021 was $632.50M.
| Period end | Proceeds from Convertible Debt 3 month | Proceeds from Convertible Debt 6 month | Proceeds from Convertible Debt 9 month | Proceeds from Convertible Debt 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $0.00 derived: sum of 2 quarters · filed 2025-02-19 | $0.00 10-K · filed 2025-02-19 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-01 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $0.00 derived: sum of 2 quarters · filed 2025-02-19 | $575.00M 10-K · filed 2025-02-19 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $575.00M 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $575.00M 10-Q · filed 2024-08-01 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $0.00 derived: sum of 2 quarters · filed 2025-02-19 | $0.00 10-K · filed 2025-02-19 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $0.00 derived: sum of 2 quarters · filed 2023-02-22 | $632.50M 10-K · filed 2023-02-22 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $632.50M 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $632.50M 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $0.00 derived: sum of 2 quarters · filed 2023-02-22 | $0.00 10-K · filed 2023-02-22 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-04 | |||
| 2019-12-31 | $109.50M 10-K · filed 2021-02-24 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 | |||
| 2016-12-31 | $0.00 10-K · filed 2017-03-01 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-03-01 | |||
| 2014-12-31 | $487.04M 10-K · filed 2017-03-01 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 | |||
| 2012-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | $194.70M 10-K · filed 2014-03-03 | ||
| 2012-09-30 | $194.69M 10-Q · filed 2013-11-05 | |||
| 2008-12-31 | $5.00M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |